OR WAIT null SECS
© 2021 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
June 01, 2021
Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.
Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.
An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.
A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.